HCMV: Natural Treatment Against Human Cytomegalovirus Found Effective in Clinical Study Conducted by CBCD

Share Article

Gene-Eden-VIR safely and effectively decreases symptoms in individuals infected with the Human Cytomegalovirus (HCMV) (1). The Center for the Biology of Chronic Disease (CBCD) points out a new clinical study published on August 21, 2013 in the medical journal Pharmacology & Pharmacy.

News Image
Doctors that wish to improve strategies that target latent HCMV should consider prescribing Gene-Eden-VIR. - polyDNA

The mission of the CBCD is to find ways to decrease the concentration of foreign DNA in infected individuals. One source of foreign DNA is the Human Cytomegalovirus (HCMV). Therefore, the CBCD is excited to announce that a new clinical study showed that Gene-Eden-VIR safely and effectively decreases symptoms in individuals infected with HCMV (1). The study was published in the peer reviewed, medical journal Pharmacology & Pharmacy, in a special edition on Advances in Antiviral Drugs.

This paper is unique because it reports a clinical study on a proprietary, patent protected, natural formula in a peer reviewed, medical journal.

Study authors wrote that, “individuals infected with HCMV reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR (1).” The study authors also wrote that “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms (1).”

Other oral treatments for the cytomegalovirus are used primarily in immunocompromised patients. Studies show that HCMV quickly develops drug resistance to the oral treatments currently available. These drugs include ganciclovir, its oral prodrug valganciclovir, cidofovir, foscavir and fomivirsen. As a study published in February 2008 in the journal Current Opinion in Investigational Drugs notes, “Their use is limited because of toxicity, poor oral bioavailability, modest efficacy and the development of drug resistance (2).” No drug has been licensed for use in the treatment of congenital HCMV.

In contrast, Gene-Eden-VIR was shown to safely reduce HCMV symptoms in the general population with no evidence of toxicity. In fact, study participants “reported no side effects after taking Gene-Eden-VIR (1).”

Doctors that wish to improve strategies that target latent HCMV should consider prescribing Gene-Eden-VIR since HCMV causes infectious mononucleosis and “Human CMV (HCMV) is an opportunistic pathogen associated with significant morbidity and mortality among immunocompromised patients (in particular immunosuppressed patients with stem cell or solid organ transplantation, AIDS or cancer). Additionally, congenital HCMV infections are a leading cause of birth defects and infections in children, occurring in 1 to 2% of all live births (2).”

The Center encourages doctors and other medical professionals to view the entire paper on Gene-Eden-VIR, at: http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101

References:

(1)    http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101
(2)    http://www.ncbi.nlm.nih.gov/pubmed/18246516

The Center for the Biology of Chronic Disease (CBCD, http://www.cbcd.net) is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments.

The CBCD published the “Purple” book by Dr. Hanan Polansky. The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between foreign DNA and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Hanan Polansky
Center for the Biology of Chronic Disease (CBCD)
+1 (585) 250-9999
Email >
Visit website